Wintest
6721
Osaka Yuka Industry
4124
D. Western Therapeutics Institute
4576
Asiro
7378
Hamee
3134
(FY)Mar 31, 2024 | (FY)Mar 31, 2023 | |
---|---|---|
Total revenue | 41.95%9.9B | 6.97B |
Cost of revenue | 97.58%4.51B | 2.28B |
Gross profit | 14.90%5.39B | 4.69B |
Operating expense | 16.78%3.05B | 2.61B |
Operating profit | 12.55%2.34B | 2.08B |
Net non-operating interest income (expenses) | 105.96%56K | -939K |
Non-operating interest income | 1.82%56K | --55K |
Non-operating interest expense | --0 | --994K |
Net investment income | 23.50%-6.12M | -7.99M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||
Gain(Loss) on derecognition of available-for-sale financial assets | ||
Income from associates and other participating interests | ||
Special income (charges) | 99.80%-385K | -196.79M |
Less:Other special charges | -99.80%385K | --196.79M |
Other non-operating income (expenses) | -274.63%-8.98M | 5.14M |
Income before tax | 23.74%2.33B | 1.88B |
Income tax | 49.53%842.47M | 563.42M |
Net income | 12.70%1.48B | 1.32B |
Net income continuous operations | 12.70%1.48B | --1.32B |
Noncontrolling interests | ||
Net income attributable to the company | 12.70%1.48B | 1.32B |
Preferred stock dividends | ||
Other under preferred stock dividend | 0 | 0 |
Net income attributable to common stockholders | 12.70%1.48B | 1.32B |
Gross dividend payment | ||
Basic earnings per share | 12.70%35.8856 | 31.8415 |
Diluted earnings per share | 12.70%35.8856 | 31.8415 |
Dividend per share | ||
Currency Unit | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP |